Schedule of Contractual Clinical Trials (Details) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Mar. 31, 2025 |
Jun. 30, 2025
USD ($)
Integer
|
|||
| Other Commitments [Line Items] | ||||
| Remaining financial contractual commitment | $ 293,000 | |||
| Phase 1b 2 [Member] | ||||
| Other Commitments [Line Items] | ||||
| Clinical trial, description | LB-100 combined with dostarlimab in ovarian clear cell carcinoma (Phase 1b/2) | |||
| Estimated Start Date | January 2024 | |||
| Estimated End Date | December 2027 | |||
| Number of Patients in Trial | Integer | 21 | |||
| Expected Date | December 2026 | |||
| Remaining financial contractual commitment | [1] | $ 0 | ||
| Phase 1b [Member] | ||||
| Other Commitments [Line Items] | ||||
| Clinical trial, description | LB-100 combined with atezolizumab in microsatellite stable metastatic colorectal cancer (Phase 1b) | |||
| Estimated Start Date | August 2024 | |||
| Estimated End Date | December 2026 | |||
| Number of Patients in Trial | Integer | 37 | |||
| Expected Date | June 2026 | |||
| Remaining financial contractual commitment | [1] | $ 0 | ||
| Phase 1b Two [Member] | ||||
| Other Commitments [Line Items] | ||||
| Clinical trial, description | LB-100 combined with doxorubicin in advanced soft tissue sarcoma (Phase 1b) | |||
| Estimated Start Date | June 2023 | |||
| Estimated End Date | Recruitment completed September 2024 | |||
| Number of Patients in Trial | Integer | 14 | |||
| Expected Date | December 2025 | |||
| Remaining financial contractual commitment | $ 293,000 | |||
| ||||